ArticleExperimental and therapeutic medicine2017
Microarray profiling of long non-coding RNAs associated with idiopathic pulmonary arterial hypertension.
Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- LncRNA-536 and RNA-Binding Protein RBM25 Interactions in Pulmonary Artery Smooth Muscle Cells: Implications in Pulmonary Hypertension.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- Emerging role of long non-coding RNAs in pulmonary hypertension and their molecular mechanisms (Review).Experimental and therapeutic medicine · 2020Review
- Aberrant expression of long non-coding RNAs (lncRNAs) is involved in brain glioma development.Archives of medical science : AMS · 2020Article
- Analysis of lncRNA-miRNA-mRNA Interactions in Hyper-proliferative Human Pulmonary Arterial Smooth Muscle Cells.Scientific reports · 2019Article
- Long non-coding RNAs influence the transcriptome in pulmonary arterial hypertension: the role of PAXIP1-AS1.The Journal of pathology · 2019Article
- LncRNA H19 promotes the proliferation of pulmonary artery smooth muscle cells through ATRespiratory research · 2018Article
Corrections and comments
- Retraction · 2019-07-17Copyright Claims · Error in Data · Lack of Approval from Author ·
- Retracted
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disease with a poor prognosis and the molecular pathways underlying the pathogenesis of IPAH are not fully understood. In the present study, the long non-coding RNA (lncRNA) and mRNA expression profiles of lymphocytes obtained from 12 IPAH patients and 12 healthy controls were analyzed using Arraystar Human lncRNA Microarray v2.0, and their roles in the pathogenesis of IPAH were characterized using comprehensive bioinformatic tools. A total of 2,511 lncRNAs (2,004 upregulated and 507 downregulated) and 1,169 mRNAs (609 upregulated and 560 downregulated) were aberrantly expressed in IPAH patients with a fold-change of >2.0. Gene ontology analysis indicated that the coexpressed lncRNAs and mRNAs were involved in the process of translation, while pathway analysis indicated that the coexpressed RNAs were enriched during the process of oxidative phosphorylation and in the ribosome. It was concluded that dysregulated lncRNAs are potentially associated with IPAH, and aberrant lncRNA expression in blood cells may serve as a diagnostic marker of IPAH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.